{"product_id":"dcgo-vrio-analysis","title":"DocGo Inc. (DCGO): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eIs DocGo Inc. (DCGO) truly positioned for sustained success in today's market? Our deep-dive VRIO analysis rigorously tests the core of its operations, scrutinizing the Value, Rarity, Inimitability, and Organization of its key assets. Uncover immediately whether these elements forge an unbeatable competitive advantage or reveal critical vulnerabilities that demand your attention below.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eDocGo Inc. (DCGO) - VRIO Analysis: Integrated Mobile Health and Medical Transportation Platform\n\u003c\/h2\u003e\n\n\u003cp\u003eYou’re looking at DocGo Inc. (DCGO) and trying to figure out if their tech stack - the blend of mobile health and medical transport - is a real moat or just a nice feature. Honestly, the tight integration is their current edge, but the market is moving fast, so we need to see if they can lock it in.\u003c\/p\u003e\n\n\u003ch\u003eIntegrated Mobile Health and Medical Transportation Platform\u003c\/h\u003e\n\u003cp\u003eThe core value proposition here is bridging the physical gap with the virtual one. Think about a patient being discharged from the hospital; they need transport and follow-up telehealth. DocGo Inc. aims to handle both in one flow, which is critical for complex patient journeys like transitions of care.\u003c\/p\u003e\n\u003cp\u003eFor context, in the third quarter of 2025, their Transportation Services revenue was actually quite solid at \u003cstrong\u003e$50.1 million\u003c\/strong\u003e, slightly up from $48.0 million the year prior. But the Mobile Health Services revenue was down to \u003cstrong\u003e$20.7 million\u003c\/strong\u003e from $90.7 million in Q3 2024, largely due to winding down migrant programs. Still, the combined offering is what matters for payer contracts.\u003c\/p\u003e\n\n\u003ch\u003eValue: Bridging Physical and Virtual Care\u003c\/h\u003e\n\u003cp\u003eThe platform’s value centers on solving the last-mile problem in healthcare delivery. It’s not just about having a telehealth app; it’s about getting the right clinician to the patient’s home with the right diagnostic tools when a virtual visit isn't enough. This is where the transport capability becomes a feature, not just a separate business line.\u003c\/p\u003e\n\u003cp\u003eThe organizational alignment is showing up in new contracts. For example, DocGo Inc. is set to launch Longitudinal Care Services in Q4 2025 for a California health plan, targeting \u003cstrong\u003e10,000 plan members\u003c\/strong\u003e who are under-engaged in their care. That’s a concrete example of value creation.\u003c\/p\u003e\n\n\u003ch\u003eRarity: Unique Operational Integration\u003c\/h\u003e\n\u003cp\u003eWhile many players offer one or the other - Amwell and Teladoc Health are huge in telehealth, and transport companies exist everywhere - the real-time, single-stack integration of both services is what makes this rare right now. It’s the operational plumbing that’s hard to copy.\u003c\/p\u003e\n\u003cp\u003eHere’s a quick comparison of their core segments based on Q3 2025 results:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003eQ3 2025 Revenue (Millions USD)\u003c\/th\u003e\n\u003cth\u003eQ3 2024 Revenue (Millions USD)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTransportation Services\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$50.1\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e$48.0\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMobile Health Services\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$20.7\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e$90.7\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$70.8\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e$138.7\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eWhat this estimate hides is the potential revenue synergy when transport feeds directly into mobile health scheduling.\u003c\/p\u003e\n\n\u003ch\u003eImitability: Moderate Difficulty to Replicate\u003c\/h\u003e\n\u003cp\u003eReplicating the technology platform is one thing; replicating the operational network and payer relationships built around that integrated service is another. Competitors like Teladoc Health and Amwell have massive scale in virtual care, but they would need to build or acquire a comparable, deeply integrated mobile fleet and scheduling system.\u003c\/p\u003e\n\u003cp\u003eThe imitation hurdle is moderate because:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCompetitors are already established in telehealth.\u003c\/li\u003e\n\u003cli\u003eBuilding the field clinician network takes significant time and capital.\u003c\/li\u003e\n\u003cli\u003eThe specific integration logic for seamless handoffs is proprietary.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eIt’s not impossible, but it’s definitely not a weekend project for a rival.\u003c\/p\u003e\n\n\u003ch\u003eOrganization: Alignment on Combined Services\u003c\/h\u003e\n\u003cp\u003eYes, DocGo Inc. appears organized around this integrated model. The CEO, Lee Bienstock, pointed to the success of their care gap closure programs as the reason for expanding into Longitudinal Care. That shows management is prioritizing and investing in the combined offering.\u003c\/p\u003e\n\u003cp\u003eThe company is actively managing its balance sheet to support this focus. As of September 30, 2025, they held about \u003cstrong\u003e$95.2 million\u003c\/strong\u003e in cash, which they are using to fund operations while aggressively cutting SG\u0026amp;A. Defintely a sign of focus.\u003c\/p\u003e\n\n\u003ch\u003eCompetitive Advantage: Temporary\u003c\/h\u003e\n\u003cp\u003eRight now, the tight integration is a clear, temporary competitive advantage. It allows them to promise and deliver better continuity of care, which payers value for quality scores. However, this advantage is only sustained if they can rapidly scale this model across more states and secure deeper, long-term contracts with major national payers.\u003c\/p\u003e\n\u003cp\u003eIf they miss the Q4 2025 launch window or if a larger player like Amwell buys a regional NEMT (Non-Emergency Medical Transportation) provider and forces integration, this edge erodes quickly. For the full year 2025, they are guiding revenue between \u003cstrong\u003e$315-$320 million\u003c\/strong\u003e, and achieving that while focusing on higher-margin payer work is the key metric to watch for sustainability.\u003c\/p\u003e\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eDocGo Inc. (DCGO) - VRIO Analysis: Proprietary Digital Transportation Management Platform\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Drives business efficiencies for hospital networks and providers by coordinating discharge and ambulance services.\u003c\/p\u003e\n\u003cp\u003eThe platform supports the Transportation Services segment, which generated $193.5 million in revenue for the full-year 2024. For the first quarter of 2025, Medical Transportation Revenue was $50.8 million.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Yes. This specific platform, integrated with their mobile health arm, is unique to DocGo Inc.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High. Software can be reverse-engineered or built by well-funded competitors over time.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Yes, they are ramping services using this platform, like the one with the New York academic medical system.\u003c\/p\u003e\n\u003cp\u003eDocGo deployed its proprietary transportation management software to centralize discharge management for a major New York academic medical system, with services commencing in July 2025.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. Technology is a necessary but rarely sustained advantage unless constantly innovated.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003ePeriod\u003c\/th\u003e\n\u003cth\u003eAmount\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Revenue\u003c\/td\u003e\n\u003ctd\u003eFull-Year 2024\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$616.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTransportation Services Revenue\u003c\/td\u003e\n\u003ctd\u003eFull-Year 2024\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$193.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Revenue\u003c\/td\u003e\n\u003ctd\u003eQ1 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$96 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdjusted EBITDA\u003c\/td\u003e\n\u003ctd\u003eQ1 2025\u003c\/td\u003e\n\u003ctd\u003eLoss of \u003cstrong\u003e$3.9 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Cash and Cash Equivalents\u003c\/td\u003e\n\u003ctd\u003eDecember 31, 2024\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$107.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eFull-year 2025 revenue guidance is expected to be \u003cstrong\u003e$300-$330 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eFull-year 2026 revenue is expected to be \u003cstrong\u003e$280-$300 million\u003c\/strong\u003e, excluding migrant-related revenue.\u003c\/li\u003e\n\u003cli\u003eThe company reported a net loss of \u003cstrong\u003e$11.1 million\u003c\/strong\u003e for Q1 2025.\u003c\/li\u003e\n\u003cli\u003eA subsidiary won a $3.4 million contract for medical transportation services to the Albany Stratton VA Medical Center.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eDocGo Inc. (DCGO) - VRIO Analysis: Payer \u0026amp; Provider Contract Portfolio\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides stable, recurring revenue streams, as seen by the growth trajectory with a major California health plan.\u003c\/p\u003e\n\u003cp\u003eThe portfolio supports significant operational scaling, evidenced by key metrics:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCompany surpassed \u003cstrong\u003e700,000 Total Patient Lives Assigned for Care Gap Closure Programs\u003c\/strong\u003e as of February 27, 2025.\u003c\/li\u003e\n\u003cli\u003ePCP visits under new agreements are projected to grow from \u003cstrong\u003e44 in 2024\u003c\/strong\u003e to \u003cstrong\u003e10,000 in 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Many firms have contracts, but DocGo Inc.'s depth in securing multi-service contracts is notable.\u003c\/p\u003e\n\u003cp\u003eThe scale of contracted lives suggests a level of embeddedness that is not common across the industry.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low. Contractual relationships are built over years of performance and trust.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Yes, management is focused on growing these verticals, which are expected to be the core business going forward.\u003c\/p\u003e\n\u003cp\u003eManagement guidance indicates continued focus on this area, with PCP visits projected to exceed \u003cstrong\u003e40,000 in 2026\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. Deep customer relationships are hard to displace once embedded in care pathways.\u003c\/p\u003e\n\n\u003cp\u003eKey financial and operational metrics related to the business segments supporting this portfolio:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003ePeriod\/Date\u003c\/td\u003e\n\u003ctd\u003eCitation Index\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Patient Lives Assigned for Care Gap Closure Programs\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e700,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of February 27, 2025\u003c\/td\u003e\n\u003ctd\u003e8\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFull-Year 2024 Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$616.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFull Year 2024\u003c\/td\u003e\n\u003ctd\u003e6, 7, 8\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFull-Year 2023 Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$624.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFull Year 2023\u003c\/td\u003e\n\u003ctd\u003e6, 7, 8\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFull-Year 2024 Adjusted EBITDA\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$60.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFull Year 2024\u003c\/td\u003e\n\u003ctd\u003e6, 7, 8\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFull-Year 2024 Transportation Services Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$193.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFull Year 2024\u003c\/td\u003e\n\u003ctd\u003e6, 7, 8\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe growth trajectory in specific contract types is highlighted by the following projections:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eProjected PCP Visits (2024): \u003cstrong\u003e44\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eProjected PCP Visits (2025): \u003cstrong\u003e10,000\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eProjected PCP Visits (2026): Over \u003cstrong\u003e40,000\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eDocGo Inc. (DCGO) - VRIO Analysis: Care Gap Closure Service Execution\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Directly addresses payer quality scores and patient needs, driving significant volume growth in the core business.\u003c\/p\u003e\n\u003cp\u003eThe Care Gap Closure and transitions of care business more than quadrupled when comparing Q3 2025 to Q3 2024, showing a year-over-year increase of \u003cstrong\u003e320%\u003c\/strong\u003e in Q3 2025 versus Q3 2024.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Many firms offer remote monitoring, but DocGo Inc. has demonstrated high-volume execution, surpassing \u003cstrong\u003e1.3 million patients assigned\u003c\/strong\u003e by Q3 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate. The process is replicable, but achieving their reported volume growth is difficult.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Yes, they are increasing investment here, showing management commitment to this area.\u003c\/p\u003e\n\u003cp\u003eManagement made \u003cstrong\u003esubstantial investments\u003c\/strong\u003e into care gap and primary care offerings in 2025, with the expectation that the rate of investment will \u003cstrong\u003edecline considerably in 2026\u003c\/strong\u003e as early markets mature.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. Success breeds competition; sustained advantage requires continuous process improvement.\u003c\/p\u003e\n\u003cp\u003eKey operational metrics supporting the execution of the Care Gap Closure service:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eData Point\u003c\/td\u003e\n\u003ctd\u003eTimeframe\/Context\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAssigned Patients (Cumulative)\u003c\/td\u003e\n\u003ctd\u003eSurpassed \u003cstrong\u003e1.3 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eBy Q3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAssigned Patients (Sequential)\u003c\/td\u003e\n\u003ctd\u003eUp from \u003cstrong\u003e1.2 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eQ2 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCare Gap Closure \u0026amp; Transitions of Care Growth\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e320%\u003c\/strong\u003e increase\u003c\/td\u003e\n\u003ctd\u003eQ3 2025 vs. Q3 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProjected Visits (Specific Customer)\u003c\/td\u003e\n\u003ctd\u003eExpected to reach over \u003cstrong\u003e17,000\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e2026 projection\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProjected Growth (Specific Customer)\u003c\/td\u003e\n\u003ctd\u003eExpected growth of \u003cstrong\u003e280%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e2025 to 2026 projection\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInvestment in Area\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eSubstantial investment\u003c\/strong\u003e made\u003c\/td\u003e\n\u003ctd\u003e2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eFurther details on management commitment and future targets:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eManagement expects to increase care gap visits to more than \u003cstrong\u003e54,000\u003c\/strong\u003e by the end of \u003cstrong\u003e2026\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eOne major California health plan is expected to grow visits from \u003cstrong\u003e4,500\u003c\/strong\u003e in 2025 to over \u003cstrong\u003e17,000\u003c\/strong\u003e in 2026.\u003c\/li\u003e\n\u003cli\u003eThe company received a substantial list from a major health plan to offer services to \u003cstrong\u003e10,000 members\u003c\/strong\u003e, launching in Q4 and ramping in early 2026.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eDocGo Inc. (DCGO) - VRIO Analysis: Dedicated Field Staff \u0026amp; Clinical Network\n\u003c\/h2\u003e\n\u003cp\u003eThe dedicated field staff and clinical network represent a core operational asset for DocGo Inc. in delivering its mobile health services.\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eThe dedicated, certified field staff enables high-quality, in-home care delivery, which is critical for preventative and chronic care management services. This capability supports the scaling of patient care outside traditional facility settings. As of February 27, 2025, the number of patient lives assigned for care gap closure programs had increased to more than \u003cstrong\u003e700,000\u003c\/strong\u003e, up from just \u003cstrong\u003e2,000\u003c\/strong\u003e a little over a year prior.\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eMaintaining a large, directly employed and certified field staff offers a degree of rarity compared to models heavily reliant on third-party contractors or gig economy workers, ensuring greater control over service quality and deployment. As of December 31, 2024, DocGo reported a total of \u003cstrong\u003e4,407\u003c\/strong\u003e employees, comprising \u003cstrong\u003e3,404\u003c\/strong\u003e full-time and \u003cstrong\u003e1,003\u003c\/strong\u003e part-time staff.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eDate\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Employees\u003c\/td\u003e\n\u003ctd\u003eDecember 31, 2024\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e4,407\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFull-Time Employees\u003c\/td\u003e\n\u003ctd\u003eDecember 31, 2024\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e3,404\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePart-Time Employees\u003c\/td\u003e\n\u003ctd\u003eDecember 31, 2024\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1,003\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatient Lives Assigned (Cumulative)\u003c\/td\u003e\n\u003ctd\u003eFebruary 2025\u003c\/td\u003e\n\u003ctd\u003eMore than \u003cstrong\u003e700,000\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFull-Year Revenue\u003c\/td\u003e\n\u003ctd\u003e2023\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$624.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eRecruiting, vetting, onboarding, and retaining a large, high-quality clinical workforce presents a significant operational hurdle, making this asset costly and time-consuming to imitate. The growth in the workforce demonstrates this scaling effort: employee count grew from \u003cstrong\u003e2,924\u003c\/strong\u003e on December 31, 2021, to \u003cstrong\u003e4,407\u003c\/strong\u003e on December 31, 2024.\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eDocGo demonstrates organizational capacity to attract and retain this talent, evidenced by external recognition and internal development metrics.\n\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eDocGo was named one of the 2025-2026 Best Companies to Work For in the Health Care and Research category by U.S. News \u0026amp; World Report.\u003c\/li\u003e\n\u003cli\u003eIn 2021, the company achieved Great Place to Work Certification™, with \u003cstrong\u003e75%\u003c\/strong\u003e of employees stating it was a great place to work, exceeding the U.S. company average by over 15 points.\u003c\/li\u003e\n\u003cli\u003eIn 2021 alone, more than \u003cstrong\u003e100\u003c\/strong\u003e employees were promoted into leadership positions, indicating structured career development paths.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\n\u003cp\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eThe competitive advantage derived from this human capital asset is considered \u003cstrong\u003eSustained\u003c\/strong\u003e due to the inherent difficulty and time required for competitors to replicate a large, experienced, and satisfied clinical workforce operating under a unified technology platform.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eDocGo Inc. (DCGO) - VRIO Analysis: Strategic Acquisition Capability (e.g., SteadyMD)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eStrategic Acquisition Capability (e.g., SteadyMD)\u003c\/strong\u003e\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eValue\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eAllows for rapid expansion of service capabilities, like enhancing telehealth with the SteadyMD acquisition, which combines DocGo's last-mile delivery with SteadyMD's nationwide virtual care platform. DocGo plans to update its 2025 revenue and adjusted EBITDA guidance following the transaction.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eRarity\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eModerate. Being able to execute M\u0026amp;A while managing a major business transition is a sign of strong corporate development. DocGo's reported cash position supported the funding, with expectations of holding over $110 million in cash and investments following significant collections.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eImitability\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eLow. Competitors can also acquire, but timing and integration success are company-specific. The acquisition closed on October 20, 2025.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eOrganization\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eYes, management explicitly mentioned using their balance sheet for M\u0026amp;A opportunities. DocGo funded the transaction through existing cash on its balance sheet, supported by a healthy current ratio of 2.36. As of a reported date, DocGo had $73.36 million in cash and $29.46 million in debt.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eTemporary. It’s an event-driven advantage; the value is realized upon successful integration. The integration combines DocGo's mobile health services with SteadyMD's 50-state virtual clinician workforce.\u003c\/p\u003e\n\u003cp\u003eThe scale and projected impact of the SteadyMD acquisition are detailed below:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eSteadyMD Data Point\u003c\/td\u003e\n\u003ctd\u003eDocGo Context\/Financials\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Acquisition Consideration\u003c\/td\u003e\n\u003ctd\u003eUp to $25 million\u003c\/td\u003e\n\u003ctd\u003eUpfront cash payment of $12.5 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProjected 2025 Revenue (SteadyMD)\u003c\/td\u003e\n\u003ctd\u003eApproximately $25 million\u003c\/td\u003e\n\u003ctd\u003eDocGo Q2 2025 Revenue was $80.4 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProjected EBITDA Positive\u003c\/td\u003e\n\u003ctd\u003eBy 2026\u003c\/td\u003e\n\u003ctd\u003eDocGo Q2 2025 EPS was -$0.11\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinician Network Size\u003c\/td\u003e\n\u003ctd\u003eOver 600 clinicians\u003c\/td\u003e\n\u003ctd\u003eDocGo's Current Ratio was 2.36\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProjected Patient Servicing (2025)\u003c\/td\u003e\n\u003ctd\u003eMore than 3 million patients\u003c\/td\u003e\n\u003ctd\u003eDocGo's Debt\/Equity ratio was 0.11\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe integration immediately provided DocGo with specific capabilities:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eA proprietary platform for real-time matching of patients with clinicians.\u003c\/li\u003e\n\u003cli\u003eA virtual care network supporting digital health companies, labs, pharmacies, and employers, including multiple Fortune 10 customers.\u003c\/li\u003e\n\u003cli\u003eThe ability to service over 3 million patients in 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eDocGo Inc. (DCGO) - VRIO Analysis: Robust Compliance and Regulatory Framework\n\u003c\/h2\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003cp\u003eMitigates legal and operational risk, which is critical when dealing with federal and state healthcare regulations. Financial health indicators include Total Shareholder Equity of \u003cstrong\u003e$260.7M\u003c\/strong\u003e and a Debt-to-Equity Ratio of \u003cstrong\u003e0.1%\u003c\/strong\u003e, suggesting a strong balance sheet foundation to support compliance infrastructure.\u003c\/p\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003cp\u003eModerate. Winning the \u003cstrong\u003e2025 MedTech Breakthrough Award\u003c\/strong\u003e for Compliance Management Innovation highlights this focus.\u003c\/p\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003cp\u003eLow. Building a culture and framework that aligns with evolving standards like the \u003cstrong\u003eDOJ 2024 Evaluation\u003c\/strong\u003e is complex.\u003c\/p\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003cp\u003eYes, the company actively uses its compliance program to strengthen corporate culture and promote transparency. The program serves as the model framework for the \u003cstrong\u003e2025 Compliance \u0026amp; Audit Work Plan\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003cp\u003eSustained. In a highly regulated industry, superior compliance reduces costly errors and builds payer trust. The program's focus on emerging technology risk management is aligned with the DOJ's updated guidance.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric Category\u003c\/th\u003e\n\u003cth\u003eSpecific Metric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eContext\/Relevance\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Health\u003c\/td\u003e\n\u003ctd\u003eTotal Shareholder Equity\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$260.7M\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eIndicates capital base supporting compliance investment.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Health\u003c\/td\u003e\n\u003ctd\u003eTotal Debt\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$249.9K\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eExtremely low debt level relative to equity, suggesting low financial strain on compliance.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Health\u003c\/td\u003e\n\u003ctd\u003eDebt-to-Equity Ratio\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e0.1%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eIndicates minimal reliance on debt financing.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Health\u003c\/td\u003e\n\u003ctd\u003eTotal Assets\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$353.8M\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eScale of operations requiring robust compliance oversight.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Health\u003c\/td\u003e\n\u003ctd\u003eMarket Capitalization (as of Nov 28, 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$102.7M\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eIndicates market valuation context for compliance risk exposure.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLiquidity\u003c\/td\u003e\n\u003ctd\u003eShort Term Assets\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$190.2M\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSupports operational continuity, including compliance functions.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompliance Recognition\u003c\/td\u003e\n\u003ctd\u003eAward Received\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2025 MedTech Breakthrough Award\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eRecognition for Compliance Management Innovation.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe compliance program's structure and effectiveness are evidenced by specific operational alignments:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eIncorporation of the \u003cstrong\u003eDepartment of Justice (DOJ) 2024 Evaluation\u003c\/strong\u003e of Corporate Compliance Programs.\u003c\/li\u003e\n\u003cli\u003eFramework for the \u003cstrong\u003e2025 Compliance \u0026amp; Audit Work Plan\u003c\/strong\u003e based on DOJ risk strategy initiatives.\u003c\/li\u003e\n\u003cli\u003eStreamlining cybersecurity procedures to improve \u003cstrong\u003eHIPAA privacy objectives\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eFocus on handling risks associated with \u003cstrong\u003enew and emerging technology\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eUse of an annual compliance survey as a confidential channel for employee reporting.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eDocGo Inc. (DCGO) - VRIO Analysis: Diversified Core Service Lines (Post-Migrant Focus)\n\u003c\/h2\u003e\n\u003cp\u003eThe strategic pivot emphasizes the resilience and stability derived from the core Medical Transportation and Payer\/Provider segments following the planned wind-down of significant, but volatile, migrant-related government programs.\u003c\/p\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003cp\u003eProvides revenue stability by shifting focus from volatile government programs to Medical Transportation and Payer\/Provider services. The evergreen business is on a solid growth trajectory. \u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eFY 2025 revenue guidance is projected to be between $315 million and $320 million, which includes an expected $68 million to $70 million from remaining migrant-related revenue.\u003c\/li\u003e\n\u003cli\u003eFY 2026 revenue guidance is projected to be between $280 million and $300 million, which includes no migrant-related revenue.\u003c\/li\u003e\n\u003cli\u003eQ3 2025 base revenue (excluding migrant programs) increased 8% year-over-year to $62.4 million from $58 million in Q3 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003cp\u003eModerate. Successfully executing a pivot away from a major revenue source (migrant programs) while maintaining core growth is rare. The core business demonstrated growth despite the significant revenue reduction from the sunsetting vertical.\u003c\/p\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003cp\u003eLow. The pivot is a strategic choice, but the underlying core services, such as technology-enabled mobile health and medical transportation, are imitable by competitors.\u003c\/p\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003cp\u003eYes, the FY 2025 guidance reflects this shift, projecting $315-$320 million in revenue, with a focus on the evergreen business. The organization is actively managing the transition and setting clear expectations for future performance based on the core segments.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eFY 2025 Adjusted EBITDA is expected to be a loss in the range of $25 million to $28 million.\u003c\/li\u003e\n\u003cli\u003eFY 2026 Adjusted EBITDA is expected to be a loss between $15 million and $25 million, with an anticipation of exiting 2026 on an adjusted EBITDA positive run rate at the top end of the revenue guidance.\u003c\/li\u003e\n\u003cli\u003eThe company paid down $30 million on its line of credit subsequent to Q2 2025, bringing the outstanding balance to $0.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003cp\u003eSustained. A resilient, diversified model is inherently more durable than a single-stream business, as evidenced by the 8% growth in base revenue in Q3 2025 while total revenue declined due to migrant program wind-down.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Metric\u003c\/td\u003e\n\u003ctd\u003eQ3 2025 Amount\u003c\/td\u003e\n\u003ctd\u003eQ3 2024 Amount\u003c\/td\u003e\n\u003ctd\u003eContext\/Growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$70.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$138.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eYear-over-year decline\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMigrant Services Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$8.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$80.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eRepresents wind-down\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBase Revenue (Ex-Migrant)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$62.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$58.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e+8%\u003c\/strong\u003e growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedical Transportation Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$50.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$48.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSegment revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMobile Health Services Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$20.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eSegment revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eDocGo Inc. (DCGO) - VRIO Analysis: Brand Reputation for Proactive, Accessible Care\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Supports new contract wins and patient engagement, as seen by the \u003cstrong\u003e250%\u003c\/strong\u003e expected growth in visits for one partner in 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Being recognized as a leader in the proactive healthcare revolution is a strong positioning statement.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High. Brand value is built over time through consistent, positive patient outcomes.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Yes, the CEO frequently emphasizes the mission to reshape the traditional healthcare system.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. A positive brand reputation, especially one tied to tangible outcomes, creates a moat.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eFinance: 13-Week Cash Flow Projection Context\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIncorporating the Q2 2025 cash position of \u003cstrong\u003e$128.7 million\u003c\/strong\u003e as the starting point for projection context:\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003ePeriod\/Date\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eStarting Cash Position (Projection Basis)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$128.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eJune 30, 2025 (Q2 End)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eActual Cash \u0026amp; Equivalents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$95.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSeptember 30, 2025 (Q3 End)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperating Cash Flow Generated\u003c\/td\u003e\n\u003ctd\u003eNearly \u003cstrong\u003e$45 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eFirst 9 Months of 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDebt Paid Down in Q3\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$30 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2025 Total Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$70.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2025 Transportation Services Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$50.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2025 Mobile Health Services Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$20.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eKey Operational and Financial Metrics:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCare Gap Closure Visits Target for 2025: More than \u003cstrong\u003e31,000\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eTotal Assigned Lives for Care Gap Closure: Exceeded \u003cstrong\u003e1.2 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eQ3 2025 Net Loss: \u003cstrong\u003e$29.7 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eQ3 2025 Adjusted EBITDA Loss: \u003cstrong\u003e$7.2 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eAI Agent Confirmed Appointments: Over \u003cstrong\u003e3,000\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eAI Agent Rescheduled Appointments: Another \u003cstrong\u003e350\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516149424277,"sku":"dcgo-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/dcgo-vrio-analysis.png?v=1740167215","url":"https:\/\/dcf-model.com\/fr\/products\/dcgo-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}